Risk factors for mortality among Human Immuno Virus infected children on antiretroviral therapy
DOI:
https://doi.org/10.18203/2349-3291.ijcp20194537Keywords:
Antiretroviral therapy, Children, HIV, Mortality, Risk factorsAbstract
Background: Children infected with HIV often reach the health care well after progression to severe immunosuppression which results in higher morbidity and mortality as compared to adults. They are vulnerable to faster disease progression compounded by susceptibility infections and social factors like attrition of caretakers. The present study delineates the factors for poor outcomes among HIV infected children.
Methods: The records of HIV infected children from 1 to 15 years of age, started on HAART, registered at ART Centre at a tertiary hospital were reviewed in the Retrospective descriptive study. The demographic details, growth parameters, clinical features, WHO staging and investigations were assessed to study the risk factors for mortality in these children.
Results: Amongst the 205 HIV infected children, enrolled in the study, the incidence of mortality was 27/205 (13.7%). The mean age of HIV infected children on ART in the no mortality and mortality group was 8.19 years and 8.25 years. The mean WHO stage of HIV infected children on ART in no mortality and mortality groups at the start of the study was 2.75 (SD=0.89) and 3.66 (SD=0.48), respectively. The mean CD4 count at start in the mortality group (195.85±105.57 cells/mm3) is significantly lower as compared to the no mortality group (306.2+355.66 cells/mm3). The mean grade of malnutrition in the no mortality and mortality groups was 1.84 and 2.88, respectively. Tuberculosis was present in 48.78% at start.
Conclusions: Presence of advanced clinical stage, immunosuppression, poor nutritional state, and shorter duration of therapy are important factors deciding outcome of the children on HAART. The intense monitoring in period post starting of HAART will ensure better outcomes.
References
WHO. Global Health Obvervatory (GHO). Number of deaths due to HIV/AIDS, 2018. Available at https://www.who.int/gho/hiv/epidemic_status/deaths_text/en/. Accessed on 10 September 2019.
WHO. Global Health Observatory (GHO data). Antiretroviral therapy coverage among all age groups. Available at: ttps://www.who.int/gho/hiv/epidemic_response/ART_text/en/. Accessed on 26 September 2019.
UNICEF. Paediatric care and treatment New York 2018 [Available at: https://data.unicef.org/topic/hivaids/paediatric-treatment-and-care/. Accessed 17 Nov 2018.
AIDS Info. U.S. Department of Health and Human Services. Available at: https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/20/50/preventing-mother-to-child-transmission-of-hiv. Accessed on 14 September 2019
Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, et al. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. The Lancet HIV. 2019 Sep 1;6(9):e623-31.
National AIDS Control Organisation. Available at: http://www.naco.gov.in/hiv factsheet. Accessed on 14 September 2019.
WHO. Paediatric HIV data and statistics, 2013. Available at: http://www.who.int/hiv/topic/paediatric/data/en/index2.html. Accessed on 14 September 2019
Mofenson LM, Korelitz J, Meyer III WA, Bethel J, Rich K, Pahwa S, et al, National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infects Dise. 1997 May 1;175(5):1029-38.
Padmapriyadarsini C, Pooranagangadevi N, Chandrasekaran K, Subramanyan S, Thiruvalluvan C, Bhavani PK, et al. Prevalence of underweight, stunting, and wasting among children infected with human immunodeficiency virus in South India. Int J Pediatr. 2009 Jul 2;2009.
Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa. PloS one. 2011 Jul 29;6(7):e22706.
Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clinical Infectious Diseases. 2007 Feb 15;44(4):599-604.
Mutanga JN, Mutembo S, Ezeamama AE, Song X, Fubisha RC, Mutesu-Kapembwa K, et al. Long-term survival outcomes of HIV infected children receiving antiretroviral therapy: an observational study from Zambia (2003-2015). BMC Public Health. 2019 Dec;19(1):115.
Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007 Dec;7(1):13.
Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acq Immune Defici Syndrom 1999. 2010 Aug 15;54(5):524.
Kabue MM, Buck WC, Wanless SR, Cox CM, McCollum ED, Caviness AC, et al. Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland. Pediatr. 2012 Sep 1;130(3):e591-9.
Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-Olupot P, et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. Aids. 2008 Nov 30;22(18):2493-9.
Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clinical infectious diseases. 2012 Sep 12;55(12):1707-18.
Taye B, Shiferaw S, Enquselassie F. The impact of malnutrition in survival of HIV infected children after initiation of antiretroviral treatment (ART). Ethiop Medi J. 2010 Jan;48(1):1-0.
Nugent J, Edmonds A, Lusiama J, Thompson D, Behets F, Pediatric HIV Care and Treatment Group. Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy in a resource-deprived setting. Pediat Infect Disease J. 2014 Nov 1;33(11):1148-55.
Bong CN, Yu JK, Chiang HC, Huang WL, Hsieh TC, Schouten EJ, et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. Aids. 2007 Aug 20;21(13):1805-10.
Adem AK, Alem D, Girmatsion F. Factors affecting survival of HIV positive children taking antiretroviral therapy at Adama Referral Hospital and Medical College, Ethiopia. J AIDS Clini Resear. 2014;5(3).
Mulugeta A, Assefa H, Tewelde T, Dube L. Determinants of survival among HIV positive children on antiretroviral therapy in public hospitals, Addis Ababa, Ethiopia. Qual Prim Care. 2017;25(4):235-41.
Gebremedhin A, Gebremariam S, Haile F, Weldearegawi B, Decotelli C. Predictors of mortality among HIV infected children on anti-retroviral therapy in Mekelle Hospital, Northern Ethiopia: a retrospective cohort study. BMC public health. 2013 Dec;13(1):1047.
Rajasekaran S, Jeyaseelan L, Raja K, Ravichandran N. Demographic & clinical profile of HIV infected children accessing care at Tambaram, Chennai, India. Indian J Med Resear. 2009 Jan 1;129(1):42-9.
Shabangu P, Beke A, Manda S, Mthethwa N. Predictors of survival among HIV-positive children on ART in Swaziland. African J AIDS Resear. 2017;16(4):335-43.
Simard EP, Shiels MS, Bhatia K, Engels EA. Long-term cancer risk among people diagnosed with AIDS during childhood. Cancer Epidemiology and Prevention Biomarkers. 2012 Jan 1;21(1):148-54.
Singh E, Naidu G, Davies MA, Bohlius J. HIV-associated malignancies in children. Current Opinion in HIV and AIDS. 2017 Jan;12(1):77-83.
Wamalwa DC, Obimbo EM, Farquhar C, Richardson BA, Mbori-Ngacha DA, Inwani I, et al. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort. BMC Pediatr. 2010 Dec;10(1):33.
